A comprehensive overview of genomic imprinting in breast and its deregulation in cancer

por Goovaerts, Tine, Steyaert, Sandra, Vandenbussche, Chari A., Galle, Jeroen, Thas, Olivier, Van Criekinge, Wim, De Meyer, Tim
Publicado 2018

Proteasomal degradation of the intrinsically disordered protein tau at single-residue resolution

por Ukmar-Godec, T., Fang, P., Ibáñez de Opakua, A., Henneberg, F., Godec, A., Pan, K.-T., Cima-Omori, M.-S., Chari, A., Mandelkow, E., Urlaub, H., Zweckstetter, M.
Publicado 2020

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States

por Gish, Robert G., Cohen, Chari A., Block, Joan M., Brosgart, Carol L., Block, Timothy M., Clary, Ryan, Le, Loc T., Ninburg, Michael H., Sandt, Lorren, Kowdley, Kris V.
Publicado 2015

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Krishnan, A., Nooka, A. K., Chari, A., Garfall, A., Martin, T., Nair, S., Lin, X., Qi, K., Londhe, A., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Usmani, S.
Publicado 2022

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D...

por Weisel, K., Chari, A., Usmani, S. Z., Goldschmidt, H., Mateos, M.-V., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Moreau, P.
Publicado 2022

P876: INCIDENTAL DISCOVERY OF PROBABLE PATHOGENIC GERMLINE VARIANTS IN MULTIPLE MYELOMA PATIENTS UNDERGOING SOMATIC GENOMIC PROFILING

por Thibaud, S., Brander, T., Balwani, M., Mouhieddine, T., Melnekoff, D., Van Oekelen, O., Lagana, A., Houldsworth, J., Chari, A., Richter, J., Sanchez, L., Richard, S., Rodriguez, C., Rossi, A., Cho, H. J., Jagannath, S., Onel, K., Parekh, S.
Publicado 2022

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE...

por van de Donk, N. W. C. J, Minnema, M C, Berdeja, J G, Oriol, A, Krishnan, A, Rodríguez-Otero, P, Askari, E, Mateos, M, Costa, L. J, Verona, R, Ma, J, Girgis, S, Yang, S, Hilder, B. W, Russell, J, Goldberg, J. D, Chari, A
Publicado 2022

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP...

por Facon, T., Plesner, T., Usmani, S., Kumar, S., Bahlis, N., Hulin, C., Orlowski, R., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Pei, H., Gupta, N., Kaila, S., Matt, K., Gries, K., Carson, R., Borgsten, F., Weisel, K., Perrot, A.
Publicado 2023

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

por Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Publicado 2023

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE N...

por Rodriguez, C., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., Nathwani, N., Shah, N., Bumma, N., Jakubowiak, A., Orlowski, R. Z., Pei, H., Cortoos, A., Patel, S., Lin, T. S., Richardson, P. G., Voorhees, P. M.
Publicado 2022

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC...

por Martínez-López, J., Moreau, P., Usmani, S. Z., Garfall, A., van de Donk, N. W., San-Miguel, J. F., Oriol, A., Chari, A., Karlin, L., Mateos, M.-V., Popat, R., Nooka, A. K., Sidana, S., Trancucci, D., Verona, R., Girgis, S., Uhlar, C., Stephenson, T., Banerjee, A., Krishnan, A.
Publicado 2022

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

por Popat, R., Moreau, P., Usmani, S. Z., Garfall, A., Mateos, M.-V., San-Miguel, J. F., Oriol, A., Nooka, A. K., Rosinol, L., Chari, A., Karlin, L., Krishnan, A., Bahlis, N., Martin, T., Besemer, B., Martínez-López, J., Delforge, M., Fastenau, J., Gries, K. S., van de Donk, N. W.
Publicado 2022

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

por Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Publicado 2022

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP...

por van de Donk, N., Rasche, L., Touzeau, C., Chari, A., Schinke, C., Minnema, M., Berdeja, J., Oriol, A., Rodriguez-Otero, P., Askari, E., Mateos, M., Costa, L., Caers, J., Krishnan, A., Vishwamitra, D., Ma, J., Qin, X., Gries, K.S., Kato, K., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J., Heuck, C., Moreau, P., San-Miguel, J.
Publicado 2023

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)...

por Minnema, M.C., Chari, A., Touzeau, C., Schinke, C., Berdeja, J., Oriol, A., van, de Donk N., Otero, P.R., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., Rasche, L., Krishnan, A., Vishwamitra, D., Ma, X., Qin, X., Gries, K.S., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J.D., Heuck, C., Miguel, J.S., Moreau, P.
Publicado 2023

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM...

por Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A
Publicado 2022